View full meeting coverage »

Eyetube Meeting Coverage:

2018 Euretina Meeting

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Understanding the ALTAIR Study

  Channels: Retina | Posted 9/22/2018

Masahito Ohji, MD, details the structure and outcomes of the ALTAIR study, which examined two different treat-and-extend regimens with aflibercept (Eylea, Regeneron) in patients with wet AMD. Dr. Ohji provides data from the study’s 96-week endpoint and discusses how the two study arms were (and were not) alike.

aflibercept • AMD • Euretina Vienna • Wet AMD


1 / 12 Series: 2018 Euretina Meeting